BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1091 related articles for article (PubMed ID: 36211448)

  • 1. Characterization of cancer-related fibroblasts (CAF) in hepatocellular carcinoma and construction of CAF-based risk signature based on single-cell RNA-seq and bulk RNA-seq data.
    Yu L; Shen N; Shi Y; Shi X; Fu X; Li S; Zhu B; Yu W; Zhang Y
    Front Immunol; 2022; 13():1009789. PubMed ID: 36211448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer.
    Ren Q; Zhang P; Zhang X; Feng Y; Li L; Lin H; Yu Y
    Front Immunol; 2023; 14():1199040. PubMed ID: 37313409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction of cancer- associated fibroblasts related risk signature based on single-cell RNA-seq and bulk RNA-seq data in bladder urothelial carcinoma.
    Liu Y; Jian J; Zhang Y; Wang L; Liu X; Chen Z
    Front Oncol; 2023; 13():1170893. PubMed ID: 37124542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of single-cell RNA-seq and bulk RNA-seq data to construct and validate a cancer-associated fibroblast-related prognostic signature for patients with ovarian cancer.
    Shen L; Li A; Cui J; Liu H; Zhang S
    J Ovarian Res; 2024 Apr; 17(1):82. PubMed ID: 38627854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel signature predicts prognosis and immunotherapy in lung adenocarcinoma based on cancer-associated fibroblasts.
    Ren Q; Zhang P; Lin H; Feng Y; Chi H; Zhang X; Xia Z; Cai H; Yu Y
    Front Immunol; 2023; 14():1201573. PubMed ID: 37325647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing.
    Li T; Zhou Z; Xie Z; Fan X; Zhang Y; Zhang Y; Song X; Ruan Y
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11379-11395. PubMed ID: 37369799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating single-cell and bulk RNA sequencing to predict prognosis and immunotherapy response in prostate cancer.
    Wen XY; Wang RY; Yu B; Yang Y; Yang J; Zhang HC
    Sci Rep; 2023 Sep; 13(1):15597. PubMed ID: 37730847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated single-cell and bulk RNA sequencing analysis identifies a cancer associated fibroblast-related signature for predicting prognosis and therapeutic responses in colorectal cancer.
    Zheng H; Liu H; Ge Y; Wang X
    Cancer Cell Int; 2021 Oct; 21(1):552. PubMed ID: 34670584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer.
    Wang W; Li T; Xie Z; Zhao J; Zhang Y; Ruan Y; Han B
    J Transl Med; 2024 Jan; 22(1):57. PubMed ID: 38221616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. M2-like tumor-associated macrophage-related biomarkers to construct a novel prognostic signature, reveal the immune landscape, and screen drugs in hepatocellular carcinoma.
    Qu X; Zhao X; Lin K; Wang N; Li X; Li S; Zhang L; Shi Y
    Front Immunol; 2022; 13():994019. PubMed ID: 36177006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of Cancer-Associated Fibroblast-Related Gene Signatures in Hepatocellular Carcinoma.
    Dong W; Xie Y; Huang H
    Front Endocrinol (Lausanne); 2022; 13():884777. PubMed ID: 35733776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of an ovarian cancer omentum metastasis-related prognostic model by integrated analysis of scRNA-seq and bulk RNA-seq.
    Zhang D; Lu W; Cui S; Mei H; Wu X; Zhuo Z
    J Ovarian Res; 2022 Nov; 15(1):123. PubMed ID: 36424614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
    Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J
    J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative analysis of cancer-associated fibroblast signature in gastric cancer.
    Zhao Z; Mak TK; Shi Y; Li K; Huo M; Zhang C
    Heliyon; 2023 Sep; 9(9):e19217. PubMed ID: 37809716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.
    Zhao QJ; Zhang J; Xu L; Liu FF
    World J Gastroenterol; 2018 Aug; 24(30):3426-3439. PubMed ID: 30122881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis on heterogeneity of hepatocellular carcinoma immune cells and a molecular risk model by integration of scRNA-seq and bulk RNA-seq.
    Liu X; Li J; Wang Q; Bai L; Xing J; Hu X; Li S; Li Q
    Front Immunol; 2022; 13():1012303. PubMed ID: 36311759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive scRNA-seq Analysis and Identification of CD8_+T Cell Related Gene Markers for Predicting Prognosis and Drug Resistance of Hepatocellular Carcinoma.
    Cao L; Liu M; Ma X; Rong P; Zhang J; Wang W
    Curr Med Chem; 2024; 31(17):2414-2430. PubMed ID: 37936457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-cell and bulk RNA sequencing reveal cancer-associated fibroblast heterogeneity and a prognostic signature in prostate cancer.
    Liu W; Wang M; Wang M; Liu M
    Medicine (Baltimore); 2023 Aug; 102(32):e34611. PubMed ID: 37565899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-associated fibroblast-derived gene signature discriminates distinct prognoses by integrated single-cell and bulk RNA-seq analyses in breast cancer.
    Fang Z; Han YL; Gao ZJ; Yao F
    Aging (Albany NY); 2024 May; 16(9):8279-8305. PubMed ID: 38728370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.